HDFC Pharma and Healthcare Fund
Sectoral/ Thematic · HDFC Asset Management Company Limited
Investing ₹10,000 every month for the last 3 years would have put in ₹3.6 lakh and grown it to about ₹5.2 lakh. Be warned: in its worst stretch, ₹1 lakh briefly shrank to about ₹85,090. Its ride has historically been comparatively steady.
New to fund research? Start with the 5-minute guide. The detailed numbers below back all of this up.HDFC Pharma and Healthcare Fund is a Sectoral/ Thematic fund from HDFC Asset Management Company Limited. It has a track record of about 3.0 years. As of the latest data it carries an RS rating of 97/99 (its recent momentum versus category peers). The current NAV is ₹22.21 (as of 2026-09-16).
Growth of ₹100 - last 3 years
HDFC Pharma and Healthcare Fund returns: last 1, 3, 5 and 10 years
| Period | This fund | Category average |
|---|---|---|
| 1 month | 0.22% | -3.47% |
| 3 months | 10.11% | 2.0% |
| 6 months | 25.37% | 10.56% |
| 1 year | 24.35% | 4.78% |
Its trailing one-year return is 24.35%. Trailing returns flatter or disappoint depending on the end date you pick - the year-by-year and rolling-return sections below are a fairer read.
Year-by-year returns
| Year | HDFC Pharma and Health | Benchmark |
|---|---|---|
| 2024 | +52.2% | +39.1% |
| 2025 | +2.4% | -2.9% |
| 2026 | +25.4% | +15.2% |
HDFC Pharma and Healthcare Fund beat its benchmark in 3 of the last 3 calendar years. That is a strong hit-rate - most active funds fail to clear their index this often. Consistency against the benchmark matters more than any single great year.
Calendar-year returns show how bumpy the ride really was - an average hides the good years and the ugly ones.
What a monthly SIP in HDFC Pharma and Healthcare Fund would have made
A ₹10,000-a-month SIP, using this fund's actual NAV history. SIP returns (XIRR) differ from lumpsum CAGR because your money goes in gradually, averaging your entry price.
| SIP duration | You invested | It became | XIRR |
|---|---|---|---|
| 3 years | ₹360,000 | ₹521,572 | 26.36% |
Over 3 years, ₹360,000 invested in monthly instalments would have grown to about ₹521,572 - an XIRR of 26.36%. Figures are pre-tax and assume you stayed invested throughout.
Risk & drawdowns
| Measure | This fund | Category average |
|---|---|---|
| Worst drawdown (lifetime) | -14.91% | -26.37% |
| Worst drawdown (3Y) | -14.91% | -20.9% |
| Volatility (1Y) | 15.82% | 19.02% |
| Sharpe (3Y) | 1.65 | 0.31 |
| Sortino (3Y) | 2.58 | 0.82 |
| Beta (3Y) | 0.92 | 0.91 |
| Alpha (3Y) | 11.74% | 6.12% |
| Up capture | 104.5% | 97.13% |
| Down capture | 80.3% | 81.47% |
| Bull-market return | 50.3% | 30.78% |
| Bear-market return | 5.2% | -23.76% |
Timing matters more than people admit: the best possible 1-year stretch in HDFC Pharma and Healthcare Fund (starting 2023-10-16) gained 67.0%, while the worst (starting 2024-12-30) still made 1.7%. The worst peak-to-bottom fall HDFC Pharma and Healthcare Fund has ever put investors through is -14.91% - the real test of whether you'd have stayed invested. In falling markets (Nifty below its 200-day average) it has returned about 5.2% annualised, versus 50.3% in rising markets. It has captured roughly 104.5% of its benchmark's up-moves and 80.3% of its down-moves.
How HDFC Pharma and Healthcare Fund behaves when markets fall
When the market is falling (the Nifty below its 200-day average), HDFC Pharma and Healthcare Fund has historically returned about 5.2% annualised, versus roughly 50.3% when the market is rising. Its deepest fall on record is -14.91%. Right now it sits about 2.23% below its all-time high (last hit 2026-09-11). The real question isn't the average year - it's whether you could hold on through the worst one.
How HDFC Pharma and Healthcare Fund ranks in its category
Percentile versus its ~946 category peers - 100th is best-in-class, 50th is average. This is the fairest apples-to-apples read.
Consistency (rolling returns)
Rolling-return data isn't available for this fund yet.
What HDFC Pharma and Healthcare Fund holds
Its latest monthly portfolio disclosure. This is what your money actually owns.
Top holdings
Sector allocation
The top 10 holdings make up 54.5% of the portfolio, across 32 stocks. A higher concentration means the fund's fortunes ride on fewer names.
Portfolio overlap with similar funds
HDFC Pharma and Healthcare Fund shares LIC MF Healthcare Fund (17%), HDFC Transportation and Logistics Fund (0%), ICICI Prudential Transportation And Logistics Fund (0%) of its portfolio with these category peers (overlap = the slice of the two portfolios invested in the same stocks). The lower the overlap, the more genuinely different the portfolios are.
Who manages HDFC Pharma and Healthcare Fund - and how good are they?
HDFC Pharma and Healthcare Fund is managed by Dhruv Muchhal and Nikhil Mathur. Below is each manager's complete track record - every fund they currently run, judged on the same numbers as everything else on this page - so you can see whether this fund is in strong hands or is the outlier in a weak book.
Dhruv Muchhal's full record
Dhruv Muchhal currently runs 36 funds, across Aggressive Hybrid Fund, Banking and PSU Fund, Conservative Hybrid Fund, Credit Risk Fund and more, with about ₹541,304 Cr under management. The book's average King Score is 66.5/100. Their strongest fund by King Score is HDFC Transportation and Logistics Fund (89/100); HDFC Pharma and Healthcare Fund ranks #33 of 36 in their book.
Tap any column heading to sort.
| # | Fund | RS | King | 3M | 6M | 1Y | 3Y CAGR | 5Y CAGR | 10Y CAGR | Sharpe | Roll 3Y | Worst fall |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | HDFC Transportation and Logistics Fund | 82 | 89 | 8.3% | 16.7% | 7.7% | 24.1% | n/a | n/a | 0.98 | n/a | -23.5% |
| 2 | HDFC Medium Term Debt Fund | 84 | 87 | 1.7% | 3.5% | 6.7% | 7.8% | 6.7% | 7.5% | 1.06 | 8.2% | -3.5% |
| 3 | HDFC Liquid Fund | 88 | 86 | 1.6% | 3.4% | 6.6% | 7.0% | 6.3% | 6.1% | 1.22 | 6.8% | -0.2% |
| 4 | HDFC Value Fund | 86 | 84 | 2.6% | 9.0% | 5.5% | 14.8% | 13.5% | 14.3% | 0.57 | 17.2% | -43.9% |
| 5 | HDFC Defence Fund | 87 | 83 | 3.6% | 21.2% | 20.6% | 36.0% | n/a | n/a | 1.06 | n/a | -34.5% |
| 6 | HDFC Ultra Short Term Fund | 81 | 82 | 1.8% | 3.4% | 6.5% | 7.2% | 6.5% | n/a | 1.33 | 6.0% | -1.0% |
| 7 | HDFC Short Term Debt Fund | 78 | 80 | 1.2% | 2.8% | 5.7% | 7.5% | 6.5% | 7.4% | 0.94 | 7.9% | -2.7% |
| 8 | HDFC Income Fund | 77 | 79 | 1.2% | 2.4% | 4.2% | 6.7% | 5.7% | 5.9% | 0.09 | 6.8% | -10.6% |
| 9 | HDFC Credit Risk Debt Fund | 73 | 79 | 2.0% | 3.9% | 7.4% | 8.2% | 7.1% | 7.9% | 1.58 | 8.2% | -2.6% |
| 10 | HDFC Banking and PSU Debt Fund | 66 | 79 | 1.0% | 2.6% | 5.2% | 7.1% | 6.2% | 7.2% | 0.46 | 7.9% | -3.1% |
| 11 | HDFC Flexi Cap Fund | 45 | 79 | 1.8% | 4.6% | 0.3% | 14.5% | 16.5% | 15.7% | 0.62 | 17.8% | -41.8% |
| 12 | HDFC Focused Fund | 41 | 78 | 0.9% | 2.7% | -2.0% | 14.2% | 17.5% | 14.5% | 0.61 | 17.1% | -45.6% |
| 13 | HDFC Hybrid Debt Fund | 68 | 77 | 0.1% | 0.9% | 1.9% | 7.1% | 7.7% | 8.3% | 0.15 | 10.3% | -12.1% |
| 14 | HDFC Long Duration Debt Fund | 74 | 76 | 0.7% | 1.6% | 2.3% | 5.8% | n/a | n/a | -0.17 | 6.4% | -6.0% |
| 15 | HDFC Equity Savings Fund | 64 | 75 | 0.7% | 1.9% | 2.4% | 8.0% | 8.1% | 9.6% | 0.3 | 11.4% | -16.9% |
| 16 | HDFC Mid Cap Fund | 60 | 75 | 2.1% | 8.6% | 5.7% | 16.6% | 18.1% | 17.2% | 0.63 | 23.3% | -39.5% |
| 17 | HDFC Gilt Fund | 52 | 75 | 0.9% | 1.8% | 3.5% | 6.3% | 5.4% | 6.0% | -0.07 | 7.3% | -11.9% |
| 18 | HDFC Dynamic Debt Fund | 82 | 71 | 1.6% | 2.7% | 4.8% | 6.6% | 5.8% | 6.2% | 0.05 | 7.1% | -7.5% |
| 19 | HDFC ELSS Tax saver | 23 | 70 | -0.5% | 0.4% | -6.1% | 11.7% | 13.5% | 13.0% | 0.39 | 15.6% | -44.1% |
| 20 | HDFC Banking & Financial Services Fund | 45 | 67 | -1.1% | 3.7% | 5.5% | 11.2% | 11.6% | n/a | 0.28 | 17.2% | -21.7% |
| 21 | HDFC Business Cycle Fund | 71 | 65 | 4.8% | 13.4% | 2.1% | 10.6% | n/a | n/a | 0.29 | 13.7% | -18.0% |
| 22 | HDFC Large and Mid Cap Fund | 40 | 64 | 0.4% | 5.7% | -0.5% | 11.8% | 13.8% | 14.4% | 0.34 | 17.0% | -39.5% |
| 23 | HDFC Large Cap Fund | 58 | 60 | -0.5% | 0.8% | -3.5% | 8.0% | 10.5% | 12.2% | 0.11 | 15.0% | -40.8% |
| 24 | HDFC Infrastructure Fund | 16 | 56 | -3.1% | 2.8% | -3.3% | 13.7% | 18.7% | 11.4% | 0.41 | 12.9% | -63.1% |
| 25 | HDFC Multi Cap Fund | 20 | 46 | -0.1% | 4.4% | -3.2% | 10.7% | n/a | n/a | 0.27 | 21.6% | -20.2% |
| 26 | HDFC Multi-Asset Fund | 22 | 45 | 0.2% | 0.6% | 2.7% | 11.3% | 10.7% | 11.4% | 0.62 | 12.9% | -27.1% |
| 27 | HDFC Hybrid Equity Fund | 39 | 44 | 0.2% | 0.3% | -4.7% | 5.8% | 7.9% | 10.1% | -0.07 | 13.0% | -33.6% |
| 28 | HDFC Consumption Fund | 32 | 44 | 1.4% | 6.5% | -8.9% | 10.3% | n/a | n/a | 0.24 | n/a | -23.5% |
| 29 | HDFC Small Cap Fund | 7 | 41 | 1.8% | 9.7% | -3.0% | 10.2% | 14.4% | 17.5% | 0.22 | 21.2% | -48.3% |
| 30 | HDFC Housing Opportunities Fund | 7 | 37 | -3.9% | -0.4% | -6.7% | 8.4% | 10.8% | n/a | 0.11 | 18.1% | -42.2% |
| 31 | HDFC MNC Fund | 59 | 33 | 3.0% | 10.2% | 0.6% | 6.8% | n/a | n/a | 0.03 | 8.7% | -24.5% |
| 32 | HDFC Technology Fund | 43 | 21 | 7.3% | 4.7% | -13.7% | 5.5% | n/a | n/a | -0.04 | n/a | -29.7% |
| 33 | HDFC Pharma and Healthcare Fund (this page) | 97 | n/a | 10.1% | 25.4% | 24.4% | n/a | n/a | n/a | 1.65 | n/a | -14.9% |
| 34 | HDFC Innovation Fund | 91 | n/a | 10.5% | 21.2% | 14.3% | n/a | n/a | n/a | n/a | n/a | -12.2% |
| 35 | HDFC Manufacturing fund | 66 | n/a | 2.7% | 10.9% | 5.1% | n/a | n/a | n/a | 0.04 | n/a | -21.5% |
| 36 | HDFC Diversified Equity All Cap Active FOF | n/a | n/a | 0.5% | 4.1% | n/a | n/a | n/a | n/a | n/a | n/a | -13.6% |
Nikhil Mathur's full record
Nikhil Mathur currently runs 2 funds, across Sectoral/ Thematic, with about ₹2,893 Cr under management. The book's average King Score is 33.0/100. Their strongest fund by King Score is HDFC MNC Fund (33/100); HDFC Pharma and Healthcare Fund ranks #2 of 2 in their book.
Tap any column heading to sort.
| # | Fund | RS | King | 3M | 6M | 1Y | 3Y CAGR | 5Y CAGR | 10Y CAGR | Sharpe | Roll 3Y | Worst fall |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | HDFC MNC Fund | 59 | 33 | 3.0% | 10.2% | 0.6% | 6.8% | n/a | n/a | 0.03 | 8.7% | -24.5% |
| 2 | HDFC Pharma and Healthcare Fund (this page) | 97 | n/a | 10.1% | 25.4% | 24.4% | n/a | n/a | n/a | 1.65 | n/a | -14.9% |
A caveat worth keeping: funds often have co-managers, and results belong to the whole team and process rather than one person. A manager's book tells you about their range and consistency, not a guarantee of skill.
Cost & fund basics
| Detail | Value |
|---|---|
| Expense ratio (Direct) | 0.92% |
| Exit load | ≈1% if redeemed within 1 year (typical) |
| Minimum investment | ₹100 |
| Fund size (AUM) | ₹2,362 Cr |
| Age | 3.0 years |
| Plan / Option | Direct · Growth |
| Benchmark | NIFTY_PHARMA |
How HDFC Pharma and Healthcare Fund compares to peers
| Fund | RS | King | 3Y CAGR |
|---|---|---|---|
| HDFC Transportation and Logistics Fund | 82 | 89 | 24.1% |
| LIC MF Healthcare Fund | 91 | 87 | 21.4% |
| ICICI Prudential Transportation And Logistics Fund | 78 | 87 | 21.1% |
| ICICI Prudential Innovation Fund | 56 | 87 | 17.8% |
| HDFC Defence Fund | 87 | 83 | 36.0% |
| Kotak Manufacture in India Fund | 81 | 83 | 19.1% |
Overlap warning: funds in the same category often own many of the same stocks - holding several rarely adds the diversification people expect.
What these numbers mean
RS rating (1-99) ranks a fund's recent momentum against its category - higher is stronger right now. King Score (0-100) is a long-term quality composite (returns, consistency, drawdown, risk-adjusted return) versus peers. Max drawdown is the worst peak-to-bottom fall the fund has ever experienced. Rolling returns test every possible start date, so one lucky (or unlucky) entry point can't distort the picture. Every formula behind this page is public - see how we calculate every number.
HDFC Pharma and Healthcare Fund review: the bottom line
Related
Frequently asked questions
Is HDFC Pharma and Healthcare Fund a good mutual fund?
That depends on your goals and risk tolerance - this is descriptive research, not advice. On the numbers, HDFC Pharma and Healthcare Fund scores RS 97/99 within its category, and its worst drawdown was -14.91%. Compare those against your needs and the peer table above.
What is the NAV of HDFC Pharma and Healthcare Fund today?
The latest NAV is ₹22.21 (as of 2026-09-16). NAV (net asset value) is the per-unit price of the fund, published every business day by the AMC.
What is the expense ratio of HDFC Pharma and Healthcare Fund?
The Direct-plan expense ratio is 0.92% a year. The Direct plan is cheaper than the Regular plan because it carries no distributor commission - over decades that gap compounds meaningfully.
Who is the fund manager of HDFC Pharma and Healthcare Fund?
HDFC Pharma and Healthcare Fund is managed by Dhruv Muchhal; Nikhil Mathur.
Is HDFC Pharma and Healthcare Fund safe? How risky is it?
No market-linked fund is 'safe' in the fixed-deposit sense - the honest question is how deep its falls get. Its worst historical drawdown was -14.91% - ₹1 lakh briefly becoming about ₹85,090. As a sectoral & thematic fund, its risk profile is typical of that category. Look at the drawdown, volatility and bear-market figures above and ask whether you could stay invested through the bad stretches.
Is HDFC Pharma and Healthcare Fund good for SIP?
We can't tell you what to do, but here is what actually happened: a ₹10,000 monthly SIP over the last 3 years grew ₹3.6 lakh into about ₹5.2 lakh (XIRR 26.36%). SIPs average your entry price, which helps most in funds that swing hard - check the crash-behaviour section above to see how it treats investors in bad markets.
What are the SIP returns of HDFC Pharma and Healthcare Fund?
A ₹10,000/month SIP over 3 years would have grown to about ₹521,572 (an XIRR of 26.36%) on ₹360,000 invested, using the fund's actual NAV history. See the SIP table above for other durations.
Is HDFC Pharma and Healthcare Fund tax-efficient / what about capital gains?
As a sectoral & thematic fund, gains follow the rules for its asset class - equity-oriented funds are taxed differently from debt. All returns on this page are pre-tax; your actual post-tax return depends on your holding period and slab. This is descriptive information, not tax advice.
Direct or Regular plan - which is shown here?
All figures on this page are for the Direct-Growth plan (no distributor commission, lower cost). Returns are pre-tax; capital-gains tax depends on your own holding period and slab.
See HDFC Pharma and Healthcare Fund live in the MF Terminal
Everything above is a static snapshot. The terminal is where you actually research it:
- Interactive price chart with EMAs & RSI
- The RS line plotted against its benchmark
- Full holdings, sector mix & portfolio overlap
- Point-in-time backtester & portfolio doctor
- Compare it side-by-side with any peer
- Screen 1,600+ funds on the same metrics
Data: AMFI NAV history, NSE indices, BSE StAR and monthly disclosures. All figures are pre-tax. Descriptive research and education only - nothing here is investment advice or a recommendation to buy, sell or hold any fund. Past performance does not guarantee future returns.